精准医疗技术研究商Virchow Medical筹集了400万美元种子轮融资，以推进活检样本管理并扩大精准肿瘤学的可及性-动脉网

Virchow Raises $4 Million to Advance Biopsy Specimen Stewardship and Expand Access to Precision Oncology

vcaonline 等信源发布 2026-03-24 23:25



可切换为仅中文







Virchow Raises $4 Million to Advance Biopsy Specimen Stewardship and Expand Access to Precision Oncology

维尔乔筹集400万美元以推进活检样本管理并扩大精准肿瘤学的可及性

Cerberus Ventures leads financing alongside five physician users of Virchow’s biopsy technologies

赛博勒斯风险投资公司与使用维尔肖活检技术的五位医生用户共同主导融资。

LA JOLLA, Calif., March 24, 2026-- Virchow Medical, Inc., manufacturer of the Crow’s Nest® Biopsy Catchment System and operator of the Virchow VaultTM Liquid Specimen Biorepository, today announced it has completed a $4 million seed financing led by Cerberus Ventures. Chenny Zhang of Cerberus Ventures will join the Virchow Board of Directors..

加利福尼亚州拉霍亚，2026年3月24日——生产Crow’s Nest®活检收集系统并运营Virchow VaultTM液体标本生物样本库的Virchow Medical公司今天宣布，已完成由Cerberus Ventures领投的400万美元种子轮融资。Cerberus Ventures的张琛妮将加入Virchow董事会。

The working capital will be used to complete the development of the world’s first liquid specimen biorepository, the Virchow Vault, and deploy Biopsy Catchment® pilot programs at additional medical institutions across the United States.

营运资金将用于完成世界上第一个液体样本生物库（Virchow Vault）的开发，并在美国各地的其他医疗机构部署Biopsy Catchment®试点项目。

Today, oncologists ordering genomic sequencing must rely on formalin-fixed tissue harvested in a patient’s biopsy procedure, which is often not available, and even when available is insufficient for clinical lab molecular diagnostics. At the same time, tens of thousands of dislodged tumor cells are generally wasted when the biopsy needle used is discarded.

今天，肿瘤学家在进行基因组测序时必须依赖于患者活检过程中采集的甲醛固定组织，而这些组织往往无法获取，即使能够获取，也不足以用于临床实验室的分子诊断。与此同时，当使用的活检针被丢弃时，通常会有成千上万脱落的肿瘤细胞被浪费掉。

Virchow’s Crow’s Nest Biopsy Catchment System is designed to solve both those problems by capturing this otherwise wasted material. Clinical data generated from six U.S. medical institutions running Crow’s Nest concordance studies – in which the molecular testing results from standard formalin-fixed tissue specimens are compared to the molecular testing results from Liquid Companion Specimens (LCSs) from the Crow’s Nest – suggests additional benefits from using the technology.

维尔肖的“乌鸦巢”活检收集系统旨在通过捕获这些原本会浪费的材料来解决这两个问题。来自美国六个医疗机构进行的“乌鸦巢”一致性研究的临床数据表明，使用该技术还有额外的好处——这些研究将标准福尔马林固定组织样本的分子检测结果与来自“乌鸦巢”的液体伴随样本（LCSs）的分子检测结果进行了比较。

By collecting high quality molecular samples from residual cells that would otherwise be discarded, invaluable data can be extracted to offer insight into other options for cancer patients beyond chemotherapy, such as targeted immunotherapy, while reducing the need for repeat patient biopsies..

通过从原本会被丢弃的残留细胞中收集高质量的分子样本，可以提取宝贵的数据，为癌症患者提供除化疗之外的其他治疗选择，例如靶向免疫疗法，同时减少对患者重复活检的需求。

“The backing of Cerberus Ventures enables us to accelerate the education of the oncology, pathology, radiology, and reference lab communities about the clinical and financial benefits of banking high‑quality genetic material sourced from used biopsy needles,” said Alexander Arrow, MD, CEO of Virchow Medical.

“Cerberus Ventures 的支持使我们能够加速向肿瘤学、病理学、放射学和参考实验室社区宣传存储从使用过的活检针中获取的高质量遗传物质的临床和经济利益，”Virchow Medical 首席执行官 Alexander Arrow 医学博士说道。

“It’s the best way to counteract tissue insufficiency, and Virchow has the technology and resources to harness that. We are humbled and honored to be in a position to help an enormous number of cancer patients.”.

“这是应对组织不足的最佳方法，而菲尔肖拥有利用这项技术的资源和能力。我们感到谦卑和荣幸能够帮助大量的癌症患者。”

In addition to Cerberus Ventures’ investment, individuals participating in this financing include pathologists and interventional radiologists who have used Virchow’s Crow’s Nest Biopsy Catchment System and therefore experienced the benefits of creating LCSs from high-quality source material that would have normally been wasted after biopsy procedures..

除了Cerberus Ventures的投资外，参与此次融资的个人包括曾使用过Virchow的Crow's Nest活检收集系统的病理学家和介入放射科医生，他们因此亲身体验到了从原本在活检后可能被浪费的高质量源材料中创建LCS的好处。

“We see Virchow not just as a platform to improve cancer patient outcomes, but also as a differentiated data provider that can help accelerate AI benefits across the healthcare system,” said Chenny Zhang, Managing Director for Cerberus Ventures. “We have been incredibly impressed with the Virchow team’s experience and execution and look forward to this partnership in their next phase of growth.”.

“我们认为，菲尔肖不仅是一个改善癌症患者预后的平台，同时也是一个差异化数据提供商，可以帮助加速整个医疗系统的人工智能效益，”赛伯乐斯风险投资公司董事总经理张晨妮表示。“菲尔肖团队的经验和执行力给我们留下了深刻的印象，我们期待在他们下一阶段的成长中展开合作。”

About Virchow Medical, Inc.

关于维尔肖医疗公司

Formerly known as Corramedical, Inc., Virchow’s mission is to unlock critical molecular data for every cancer patient and enable precision medicine to save more lives. It does this by providing its hospital subscribers with a monthly supply of Crow’s Nest® Biopsy Catchment System units, which are used after core needle tumor biopsies to create Liquid Companion Specimens (LCSs).

以前被称为Corramedical, Inc.，Virchow的使命是为每位癌症患者解锁关键的分子数据，并推动精准医疗以拯救更多生命。它通过向医院订阅者每月提供Crow’s Nest®活检收集系统装置来实现这一目标，该系统在核心针头肿瘤活检后使用，以创建液体伴随样本（LCS）。

The company stores the LCSs for its customers in a unique biorepository, the Virchow Vault,TM housed in a CAP-accredited facility. As a result, oncologists can log on to www.virchowvault.com at any time after their patient’s biopsy and order genomic sequencing or other molecular testing without requesting their hospital’s pathology department to provide any of the tissue block.

公司将其客户的LCS存储在独特的生物样本库——Virchow Vault™中，该库位于一家获得CAP认证的设施内。因此，肿瘤科医生可以在患者活检后的任何时间登录www.virchowvault.com，订购基因组测序或其他分子测试，而无需请求医院病理科提供任何组织块。

In an era which Formalin-Fixed Paraffin-Embedded (FFPE) tissue is limited and often insufficient, this ability to order sequencing using only high-quality material that is normally discarded on used needles is designed to provide every biopsy patient the potential opportunity to be treated with precision medicine targeted therapy..

在一个福尔马林固定石蜡包埋（FFPE）组织有限且通常不足的时代，这种仅使用通常被丢弃在用过的针头上的高质量材料进行测序的能力，旨在为每位活检患者提供接受精准医学靶向治疗的潜在机会。

For further information, visit www.virchowmed.com, and follow Virchow on LinkedIn at https://www.linkedin.com/company/virchowmed/.

有关更多信息，请访问 www.virchowmed.com，并在 LinkedIn 上关注 Virchow：https://www.linkedin.com/company/virchowmed/。

Virchow Medical is an EvoNexus portfolio company.

维尔肖医药是EvoNexus投资组合中的一家公司。

Crow’s Nest®, Virchow VaultTM, Biopsy Catchment®, Precision Can’t WasteTM, and Liquid Companion SpecimenTM are trademarks of Virchow Medical, Inc.

Crow’s Nest®、Virchow Vault™、Biopsy Catchment®、Precision Can’t Waste™ 和 Liquid Companion Specimen™ 是 Virchow Medical, Inc. 的商标。

Contact:

联系：

Press contact:

媒体联系人：

Carolyn Holck